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ABSTRACT
Introduction: Attention-deficit/hyperactivity disorder
(ADHD) is a major public health issue.
Pharmacological treatments play an important role in
the multimodal treatment of ADHD. Currently, there is a
lack of up-to-date and comprehensive evidence on how
available ADHD drugs compare and rank in terms of
efficacy and tolerability, in children or adolescents as
well as in adults. We will conduct a network meta-
analysis (NMA), integrating direct and indirect
comparisons from randomised controlled trials (RCTs),
to rank pharmacological treatments for ADHD
according to their efficacy and tolerability profiles.
Methods and analysis: We will search a broad
range of electronic databases, including PubMed,
MEDLINE, EMBASE, PsycINFO, ERIC and Web of
Science, with no date or language restrictions. We will
also search for unpublished studies using international
clinical trial registries and contacting relevant drug
companies. We will identify and include available
parallel-group, cross-over and cluster randomised trials
that compare methylphenidate, dexmethylphenidate,
amphetamine derivatives (including lisdexamfetamine),
atomoxetine, clonidine, guanfacine, bupropion or
modafinil (as oral therapy) either with each other or to
placebo, in children, adolescents or adults with ADHD.
Primary outcomes will be efficacy (indicated by
reduction in severity of ADHD core symptoms
measured on a standardised scale) and tolerability (the
proportion of patients who left a study early due to
side effects). Secondary outcomes will be global
functioning, acceptability (proportion of patients who
left the study early by any cause) and changes in blood
pressure and body weight. NMA will be conducted in
STATA within a frequentist framework. The quality of
RCTs will be evaluated using the Cochrane risk of bias
tool, and the quality of the evidence will be assessed
using the GRADE approach. Subgroup and sensitivity
analyses will be conducted to assess the robustness of
the findings.
Ethics and dissemination: No ethical issues are
foreseen. Results from this study will be published in a
Strengths and limitations of this study
▪ This is the first comprehensive network
meta-analysis (NMA) addressing the efficacy and
tolerability of medications for attention-deficit/
hyperactivity disorder (ADHD) in children, ado-
lescents and adults. By integrating direct and
indirect evidence from all included studies, it will
increase the precision of treatment estimates and
allow for the ranking of available ADHD drugs in
terms of efficacy and acceptability.
▪ Subgroup and sensitivity analyses will address
important clinical questions (eg, differences
between sexes, comparison between children and
adolescents, and subgroup analysis in participants
without neurological/psychiatric comorbidities).
▪ The findings of this NMA have the potential to
inform and influence clinical decision-making
and guideline development.
▪ As with any meta-analysis, the present one will
be limited by the quality of the primary studies
included in the systematic review. To properly
address this issue, we will assess the quality of
the studies included in the systematic review and
the quality of the evidence using the Cochrane
risk of bias tool and the GRADE approach,
respectively, that are considered the gold stand-
ard for critical appraisal and quality of evidence.
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peer-reviewed journal and possibly presented at relevant national and
international conferences.
Trial registration number: CRD42014008976.
BACKGROUND
Attention-deﬁcit/hyperactivity disorder (ADHD) is a
common neurodevelopmental disorder1 characterised,
according to the Diagnostic and Statistical Manual of
Mental Disorders, ﬁfth edition (DSM-5),2 by a persistent
and impairing pattern of inattention and/or hyperactiv-
ity/impulsivity. Hyperkinetic disorder (HKD), as deﬁned
in the International Classiﬁcation of Diseases, 10th
Edition (ICD-10),3 is a narrower diagnostic category,
requiring symptoms of inattention and hyperactivity/
impulsivity, similarly to those individuals meeting criteria
for the combined presentation of ADHD as per DSM-5.2
A large body of evidence shows that ADHD is frequently
comorbid with other psychiatric conditions, the most
common of which include oppositional deﬁant disorder,
conduct disorder, speciﬁc learning disorders, mood and
anxiety disorders, substance use disorders, sleep distur-
bances and other neurodevelopmental disorders such as
autism spectrum disorder.4 5 The worldwide-pooled
prevalence of ADHD is estimated at around 5% in
school-age children1 6 albeit with a substantial hetero-
geneity between studies, accounted for by differences in
either the method of assessment or the diagnostic cri-
teria employed. Impairing symptoms of ADHD persist
into adulthood in around 65% of cases7 with a pooled
prevalence of adulthood ADHD around 2.5%.8 As a con-
sequence of the nature of the core symptoms and the
comorbid disorders, ADHD imposes a substantial
burden on society in terms of psychological dysfunction,
adverse educational and vocational outcomes, stress on
families and societal ﬁnancial costs. Average annual
incremental costs of ADHD have been estimated at
$143–$266 billion in the USA9 and are substantial in
other countries as well.10 11
Available treatments for ADHD include pharmaco-
logical and non-pharmacological interventions.
Pharmacological treatments are recommended as the ﬁrst
option in several guidelines/practice parameters,12 at
least for severe cases,13 14 or as a treatment strategy for
patients who have not responded to non-pharmacological
interventions.13 14 Medications for ADHD include psy-
chostimulant (eg, methylphenidate and amphetamine
derivatives) and non-psychostimulant drugs (eg, atomoxe-
tine, clonidine and guanfacine, among others). A large
body of evidence from double-blind randomised con-
trolled trials (RCTs), summarised in several meta-analyses
in children, adolescents and/or adults, demonstrated that
different classes of psychostimulants (eg, methylphenid-
ate15–18 or mixed amphetamine salts19 and other amphet-
amine derivatives20) and some non-psychostimulant
treatments, such as atomoxetine,21–24 are signiﬁcantly
more efﬁcacious than placebo, at least in the short term,
when considering ADHD core symptoms as main
outcome. However, two recent Cochrane reviews25 26 have
questioned the quality of the evidence from the available
RCTs, in contrast with a previous review by the National
Institute for Health and Care Excellence (NICE),13 that
assessed the quality of the evidence as high.
Importantly, previous systematic reviews or
meta-analyses also attempted to address the comparative
efﬁcacy of some available drugs for ADHD, considering
either different formulations of the same drug class27 or
different classes and agents.28 Such systematic reviews/
meta-analyses have relied on comparison of effect sizes
from individual RCTs or on the qualitative/quantitative
summary of head-to-head studies; most of them focused
on the comparison of two drugs only. Overall, evidence
from these reviews is inconclusive and/or mixed. For
example, while some of them found comparable efﬁcacy
between psychostimulants and atomoxetine,29 30 others
pointed to signiﬁcantly higher efﬁcacy of psychostimu-
lants compared with other drugs.31–33
Therefore, there is a need for meta-analytic evidence
that can provide a framework to establish a hierarchy of
the efﬁcacy and acceptability/tolerability among the
available pharmacological treatments for ADHD, in chil-
dren as well as in adults. Such evidence would be invalu-
able in day-to-day clinical practice, where clinicians are
faced with selecting speciﬁc medications for the treat-
ment of ADHD. Furthermore, given the current debate
around the appropriateness of behavioural interventions
versus medications as ﬁrst-line treatment for ADHD,34
the uncertainty on the efﬁcacy/effectiveness of non-
pharmacological treatments for ADHD core symp-
toms34 35 and the increasing trend in the prescription of
ADHD medications in some countries,34 an up-to-date
and accurate estimate of the efﬁcacy, tolerability and
safety of the most common ADHD drugs is paramount
from a public health standpoint.
Network meta-analysis (NMA) is a statistical method of
synthesising information from a network of trials that
have addressed the same question using different inter-
ventions.36 An NMA relies on the combination of direct
and indirect evidence, which can increase precision
while randomisation is preserved.37–41 Therefore, com-
pared with standard pairwise meta-analyses, NMA gives a
higher degree of precision in the estimation of efﬁcacy
and acceptability/tolerability of drugs. A further applica-
tion of the NMA methodology is the possibility of
ranking the interventions included in the network
according to their relative efﬁcacy and safety, which in
itself is highly relevant for treatment decision-making in
the daily clinical practice.
NMAs addressing the efﬁcacy and tolerability of medi-
cations for other psychiatric disorders have been instru-
mental in providing novel evidence supporting clinical
decision-making. For instance, a recent NMA concluded
that, with the possible exception of ﬂuoxetine, antide-
pressants do not seem to offer a clear advantage for the
acute treatment of major depressive disorder in children
and adolescents.42
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While previous or ongoing network meta-analyses
focused on children with ADHD only43–45 or on the com-
parison of only two medications in adults,46 the present
one, to the best of our knowledge, is the ﬁrst NMA
addressing the efﬁcacy and tolerability of a set of ADHD
medications in children as well as in adults, using strin-
gent criteria to adhere to the methodological assump-
tions underpinning the validity of an NMA (see below).
Objectives
To rank pharmacological treatments in patients with
ADHD, in terms of:
1. Overall efﬁcacy on ADHD core symptoms;
2. Tolerability;
3. Global functioning;
4. Acceptability;
5. Changes in blood pressure and weight.
METHODS
Methods for this systematic review have been developed
according to the PRISMA extension statement for
reporting of systematic reviews incorporating network
meta-analyses of healthcare interventions.47 This system-
atic review and NMA is registered in the PROSPERO
database (registration number: CRD42014008976).
Types of participants
Inclusion criteria
Studies that include children (≥5 and ≤12 years), ado-
lescents (>12 and <18 years) and/or adults (≥18 years),
either inpatients or outpatients, who: (1) meet
DSM-III, III-R, IV, IV-TR or 5 criteria for a primary diag-
nosis of ADHD or ICD-10 criteria for a primary diagno-
sis of HKD (we will not include studies using DSM-II
criteria since they did not use standardised criteria).
There will be no restriction on ADHD subtype/presen-
tation, gender, IQ or socioeconomic status of partici-
pants. As for comorbidities, we will include studies in
which some, or all, participants have one or more psy-
chiatric or neurological comorbidities (except genetic
syndromes), unless participants were pharmacologically
treated during the study for these comorbidities (eg,
antiepileptic drugs for epilepsy or mood stabilisers for
bipolar disorders).
Exclusion criteria
We will exclude: (1) studies recruiting patients with a
diagnosis of Minimal Brain Dysfunction, which would
not be comparable with DSM deﬁnitions of ADHD or
ICD deﬁnitions of HKD; (2) trials in which ADHD is a
comorbid disorder secondary to a genetic syndrome; (3)
studies enrolling participants deﬁned as ‘hyperkinetic’
or ‘hyperactive’ without application of standardised diag-
nostic criteria; (4) studies recruiting patients who were
taking ADHD medication prior to entering the study,
unless participants completed an appropriate wash out
period before starting the study trial (see table 1 for the
details about recommended washout periods for each
individual drug); (5) studies including (a) participants
who previously responded (according to the deﬁnition
provided in the study) to the same medication tested in
the randomised phase (irrespective of washout period)
or (b) participants who were responders or stabilised/
optimised to an ADHD medication (where stabilised/
optimised means responders) during a run-in/open-
label phase before of randomisation (irrespective of
wash out period); (6) studies in which all included parti-
cipants were deemed to be ‘resistant’ to a previous
ADHD drug, as this would violate the transitivity assump-
tion of NMA.36; and (7) Data from the withdrawal phase
of a trial, in which already treated participants are ran-
domised to either continue medication or switch to
placebo, following an open-label phase.
Types of interventions
We will include studies assessing any of the following
drugs, as oral monotherapy (tablets, capsules, chewable
compounds or liquid formulations), compared with
each other or with placebo: methylphenidate, dex-
methylphenidate, atomoxetine, amphetamine derivatives
(including lisdexamfetamine), clonidine, guanfacine,
bupropion and modaﬁnil. Only studies where medica-
tions were given within the licensed or recommended
dose level (see tables 2 and 3) will be included.
Fixed-dose and ﬂexible-dose designs will be allowed.
Studies assessing the efﬁcacy of multimodal treatments
including the combination of ADHD drug(s) plus psy-
chotherapy (for ADHD or other disorders/conditions)
will be excluded. Studies in which ADHD drugs of inter-
est for the present meta-analysis are combined with psy-
choeducation only, rather than psychotherapy, will be
retained. Study arms with medication only as monother-
apy will be included from these studies if comparable
with another medication only or placebo arm from the
same study. Studies comparing any ADHD drug to treat-
ment as usual or assessing the efﬁcacy of additional
drugs in participants resistant to the ﬁrst ADHD drug
will not be included. Studies using a single dose of drug
will also be excluded. In terms of minimum duration of
the pharmacological treatment, while previous
meta-analyses have included studies with treatment dur-
ation of 1 day,25 and other meta-analyses have excluded
Table 1 Washout periods
Drug Washout (days)
Methylphenidate 1
Amphetamine derivatives 3–5
Lisdexamfetamine dimesylate 2–3
Atomoxetine 1
Clonidine 3
Guanfacine 3–4
Bupropion 2–4
Modafinil 3–4
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studies lasting <3 weeks,43 we will include trials with
treatment duration of at least 7 consecutive days, since
response to adequate doses of psychostimulants can be
appreciated already after ∼1 week of treatment and, to
the best of our knowledge, there is no clear evidence
that placebo effects change over time in studies of
ADHD drugs.
Timing of outcome assessment
We will include studies assessing efﬁcacy of drugs in
the short term (outcomes up to 12 weeks) and in the
medium term (up to 26 weeks). For short-term
studies, if outcomes at different or several time-points
are reported, we will choose the outcomes at the time-
point closest to 12 weeks. For medium-term studies, if
outcomes at different or several time-points are
reported, we will choose the outcomes at the time-
point closest to 26 weeks. We will consider also longer
term outcomes (at least 52 weeks). For these studies, if
outcomes at different or several time-points are
reported, we will choose the outcomes at the time-
point closest to 52 weeks.
Table 2 Dose range of medication included in the network meta-analysis for children/adolescents, according to the FDA
whenever possible (as retrieved in https://dailymed.nlm.nih.gov/dailymed/ or http://www.accessdata.fda.gov/; other source:
Arnsten et al72)
Drug Min. daily dose Max. daily dose
Methylphenidate hydrochloride immediate
release
10 mg 60 mg
Methylphenidate hydrochloride
intermediate acting
20 mg 60 mg
Methylphenidate hydrochloride long acting 18 mg 54 mg (children)
72 mg (adolescents)
(do not exceed 2 mg/kg/day)
Methylphenidate hydrochloride oral
solution
10 mg 60 mg
Methylphenidate hydrochloride chewable
tablets
10 mg 60 mg
d,l-threo Methylphenidate slow release 20 mg 60 mg
Dexmethylphenidate
(d-threo-methylphenidate) immediate
release
5 mg 20 mg
Dexmethylphenidate
(d-threo-methylphenidate) XR
5 mg (children) 20 mg
Dextro-amphetamine immediate release 2.5 mg (children 3–5 years)
5 mg (children ≥6 years)
Children 3–5 years: not specified
Children ≥ 6-years: 40 mg
Dextro-amphetamine ER 10 mg (children 6–12 years and
adolescents 13–17 years)
30 mg (children 6–12 years)
Adolescents: not specified
Mixed amphetamine salts 2.5 mg (children 3–5 years)
5 mg (children ≥6 years)
40 mg (children ≥6 years)
Mixed amphetamine salts XR 10 mg (children ≥6 years)
10 mg, increased to 20 mg
(adolescents 13–17 years)
30 mg (children ≥6 years)
Adolescents 13–17 years and
Lisdexamfetamine 30 mg (individuals ≥6 years) 70 mg (individuals ≥ 6 years)
Atomoxetine 0.5 mg/kg (children and
adolescents ≤70 kg)
40 mg (children and
adolescents >70 kg and adults)
1.4 (1.8 in Europe) mg/kg or 100 mg,
whichever less (children and adolescents ≤
70 kg)
100 mg (children and adolescents >70 kg)
Clonidine immediate release Children/adolescents <45 kg:
0.05 mg
Children/adolescents >45 kg:
0.1 mg
Children/adolescents <45 kg: 0.2 mg
Children/adolescents > 45 kg: 0.4 mg
Clonidine extended release 0.1 mg 0.4 mg
Guanfacine immediate release 0.5 mg N/S
Guanfacine extended release 1 mg 7 mg
Bupropion IR N/S N/S
Buproprion SR N/S N/S
Bupropion XL N/S N/S
Modafinil 200 mg 400 mg
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Types of studies
Inclusion criteria
Only double-blinded RCTs will be included. Three
types of trials will be eligible for inclusion:
parallel-group RCTs, crossover trials and cluster trials.
For cross-over studies, to address concerns around pos-
sible ‘carry over’ effects,48 we will use data from the pre-
crossover phase, whenever this is reported in the paper.
When data for the precrossover phase are not reported,
we will contact study authors to gather them. If pre-
crossover data are not reported and not available on
request, we will use data at the end point (after cross-
ing over), derived from appropriate statistical methods
(ie, paired t-test),49 only if there was a washout period
(see table 1) between the two phases (precrossover and
postcrossover) of the trial. As for cluster trials, accord-
ing to the Cochrane Handbook, they can be combined
with individually randomised RCTs.50 In this case,
approximately correct analyses will be performed by
dividing the binary data (the number of participants
and the number experiencing the event) as presented
in a report by a ‘design effect’.50 This is calculated by
using the mean number of participants per cluster (m)
and the intraclass correlation coefﬁcient (ICC) (Design
effect=1+(m–1)×ICC).50 The ICC will be estimated by
using the between-cluster variance component and the
within-cluster variance component of the study.51 For
continuous data only, the sample size will be reduced;
means and SDs will remain unchanged.
Exclusion criteria
Quasi-RCTs, in which treatment assignment is decided
through methods such as alternate days of the week, or
studies using Latin square approach without adequate
randomisation will be excluded. We will also exclude
open-label or single-blind RCTs, long-term studies using
a maintenance design, and N-of-1 trials.
Types of outcome measures
Primary outcomes
▸ Efﬁcacy (as continuous outcome) on severity of
ADHD core symptoms (total combined, ie, inattentive
plus hyperactive/impulsive symptoms), measured as
end point score on a standardised scale ﬁlled out by
parents, teachers, patients or clinician(s). Where
there are ratings based on two or more scales, only
one scale will be selected among the following ones,
in the following order of preference: ADHD Rating
Scale (total score), SNAP ADHD (total score), Conners
rating scale (any version, ADHD total score) or other
ADHD scales. Total scores for ADHD symptoms will
be selected and evaluated. However, when total scores
are not available and only subscales of ADHD mea-
sures (ie, measuring the dimensions of inattention
and hyperactivity/impulsivity symptoms of ADHD sep-
arately) are reported, the effect size for each of these
will be calculated separately and aggregated to esti-
mate the overall effect. When end point scores are
not reported but change scores are, we will use the
Table 3 Dose range of medication included in the network meta-analysis for adults, according to the FDA whenever
possible (as retrieved in https://dailymed.nlm.nih.gov/dailymed/ or http://www.accessdata.fda.gov/; other sources:
http://integratedcare-nw.org/docs/PCPtraining/AdultADHDSummary-Recommendations.pdf; Arnsten et al72)
Drug Min. daily dose Max. daily dose
Methylphenidate hydrochloride immediate release 10 mg 60 mg
Methylphenidate hydrochloride intermediate acting 20 mg 60 mg
Methylphenidate hydrochloride long acting 18–36 mg 72 mg
Methylphenidate hydrochloride oral solution 10 mg 60 mg
Methylphenidate hydrochloride chewable tablets 10 mg 60 mg
d,l-threo Methylphenidate slow release 20 mg 60 mg
Dexmethylphenidate (d-threo-methylphenidate) immediate release 5 mg 20 mg
Dexmethylphenidate (d-threo-methylphenidate) XR 10 mg (adult) 20 mg
Dextro-amphetamine immediate release N/S N/S
Dextro-amphetamine ER 20 mg N/S
Mixed amphetamine salts N/S N/S
Mixed amphetamine salts XR 20 mg N/S
Lisdexamfetamine 30 mg 70 mg
Atomoxetine N/S 100 mg
Clonidine immediate release N/S N/S
Clonidine extended release 0.1 mg 0.4 mg
Guanfacine immediate release 0.5 mg N/S
Guanfacine extended release 1 mg 7 mg
Bupropion IR 100 mg two times a day 100 mg tid
Buproprion SR 150 mg qam 150 mg two times a day
Bupropion XL 150 mg qam 300 mg qam
Modafinil 200 mg 400 mg
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latter scores.52 We will conduct separate analyses for
measures rated by (1) clinicians, (2) parents, (3) tea-
chers and (4) patients (self). Teachers and clinicians’
scores will be considered for the primary analysis of
studies in children/adolescents and adults,
respectively.
▸ Tolerability of treatment, deﬁned as the proportion
of patients who left the study early due to any side
effects during the ﬁrst 12 weeks of treatment.
Secondary outcomes
▸ Global functioning, measured by the Clinical Global
Impressions-Improvement (CGI-I, investigator’s
rating), considered at time-points closest to 12 weeks,
and, if available, at 26 and 52 weeks. We will consider
the proportion of participants who improved at end-
point based on the ﬁnal CGI-I score of 1–2;
▸ Acceptability of treatment, deﬁned as the proportion
of patients who left the study early for any reason
during the ﬁrst 12 weeks of treatment, consistent with
Cipriani et al;42
▸ Change in blood pressure (diastolic and systolic),
measured in mm Hg;
▸ Change in body weight, measured in kg.
Search strategy
We will search for published and unpublished RCTs
meeting the inclusion criteria.
Electronic searches
Electronic literature search will be conducted by two
members of the Cochrane Schizophrenia Group (FS
and JX) with input from the EAGG members. The fol-
lowing search resources will be considered: PubMed,
MEDLINE, EMBASE, PsycINFO, ERIC and Web of
Science (including Science Citation Index Expanded
(SCI-EXPANDED), Social Science Citation Index
(SSCI), Conference Proceedings Citation Index-Science
(CPCI-S) and Conference Proceedings Citation
Index-Social Science and Humanities (CPCI-SSH)) via
Web of Knowledge. We will also search the following
international databases:
1. WHO International Clinical Trials Registry Platform
(ICTRP), including:
▸ Australian New Zealand Clinical Trials Registry
(ANZCTR) (including clinical trials from
Therapeutic Goods Administration (TGA))
▸ Brazilian Clinical Trials Registry (ReBec)
▸ Chinese Clinical Trial Register (ChiCTR)
▸ Clinical Research Information Service (CRiS),
Republic of Korea
▸ ClinicalTrials.gov (including clinical trials from
FDA)
▸ Clinical Trials Registry—India (CTRI)
▸ Cuban Public Registry of Clinical Trials (RPCEC)
▸ EU Clinical Trials Register (EU-CTR) (including
clinical trials from the European Medicines
Agency (EMA))
▸ German Clinical Trials Register (DRKS)
▸ Iranian Registry of Clinical Trials (IRCT)
▸ ISRCTN.org (including clinical trials from
controlled-trials.com, The Wellcome Trust (UK),
UK trials (UK), Action Medical Research (UK),
the Medicines and Healthcare products
Regulatory Agency (MHRA) and National
Research Register)
▸ Japan Primary Registries Network ( JPRN) (includ-
ing clinical trials from UMIN-CTR, JapicCTI and
JMACCT)
▸ Pan African Clinical Trial Registry (PACTR)
▸ Sri Lanka Clinical Trials Registry (SLCTR)
▸ The Netherlands National Trial Register (NTR)
▸ Thai Clinical Trials Register (TCTR)
2. The International Federation of Pharmaceutical
Manufacturers and Associations (IFPMA)
3. UK Clinical Trials Gateway
4. BIOSIS Previews via Web of Knowledge
5. SEAGLE (OpenGrey)
6. ProQuest Theses and Dissertations
7. ClinicalTrials.gov
8. http://www.fda.gov/
9. http://www.ema.europa.eu
The following search terms will be used for PubMed:
(‘Attention Deﬁcit Disorder with Hyperactivity’ (Mesh)
OR adhd(tiab) OR hkd(tiab) OR addh(tiab) OR
hyperkine*(tiab) OR ‘attention deﬁcit*’(tiab) OR hyper-
activ*(tiab) OR hyperactiv*(tiab) OR overactive(tiab)
OR inattentive(tiab) OR impulsiv*(tiab)) AND
(‘Amphetamines’(Mesh) OR ‘Bupropion’(Mesh) OR
‘Clonidine’(Mesh) OR ‘Methylphenidate’(Mesh) OR
‘Dexmethylphenidate’(Mesh) OR ‘Guanfacine’(Mesh)
OR Adderall(tiab) OR Amphetamine(tiab) OR Desoxyn*
(tiab) OR Phenopromin(tiab) OR Amfetamine(tiab) OR
Phenamine(tiab) OR Centramina(tiab) OR Fenamine
(tiab) OR Levoamphetamine(tiab) OR Dexamfetamine
(tiab) OR Dexamphetamine(tiab) OR Dexedrine(tiab)
OR Dextroamphetamine(tiab) OR DextroStat(tiab)
OR Oxydess(tiab) OR Methylamphetamine(tiab)
OR Methylenedioxyamphetamine(tiab) OR
Methamphetamine(tiab) OR Chloroamphetamine(tiab)
OR Metamfetamine(tiab) OR Deoxyephedrine(tiab) OR
Desoxyephedrine(tiab) OR Ecstasy(tiab) OR
Atomoxetine(tiab) OR Biphentin(tiab) OR Bupropion
(tiab) OR Amfebutamone(tiab) OR Zyntabac(tiab) OR
Quomen(tiab) OR Wellbutrin(tiab) OR Zyban(tiab) OR
Catapres*(tiab) OR Clonidine(tiab) OR Klofenil(tiab)
OR Clofenil(tiab) OR Chlophazolin(tiab) OR Gemiton
(tiab) OR Hemiton(tiab) OR Isoglaucon(tiab) OR
Klofelin(tiab) OR Clopheline(tiab) OR Clofelin(tiab)
OR Dixarit(tiab) OR Concerta(tiab) OR Daytrana(tiab)
OR Methylphenidate(tiab) OR Equasym(tiab) OR
Methylin(tiab) OR Tsentedrin(tiab) OR Centedrin(tiab)
OR Phenidylate(tiab) OR Ritalin*(tiab) OR Duraclon
(tiab) OR Elvanse(tiab) OR Focalin(tiab) OR
Dexmethylphenidate(tiab) OR Guanfacine(tiab) OR
Estulic(tiab) OR Tenex(tiab) OR Kapvay(tiab) OR
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Lisdexamfetamine(tiab) OR Vyvanse(tiab) OR
Medikinet(tiab) OR Metadate(tiab) OR Modaﬁnil(tiab)
OR Nexiclon(tiab) OR Quillivant(tiab) OR Strattera
(tiab)) AND (randomized controlled trial(pt) OR con-
trolled clinical trial(pt) OR randomized(tiab) OR
placebo(tiab) OR clinical trials as topic(mesh:noexp) OR
randomly(tiab) OR trial(ti)) NOT (animals(mh) NOT
humans(mh))
Search terms and syntax will be adapted as required
for each of the databases.
Reference lists and other sources
The references of all selected studies will be searched
for other published reports and citations of unpublished
studies. Relevant review papers will be checked. In addi-
tion, websites of the most relevant pharmaceutical com-
panies manufacturing ADHD drugs will be
hand-searched for published, unpublished and ongoing
controlled trials. Companies producing ADHD drugs
will also be contacted to inquire about any additional
relevant study. New trials which have been completed
will be included if usable data are provided by the
pharmaceutical company.
Identification and selection of studies
Studies identiﬁed through electronic and manual
searches will be listed with citation, titles and abstracts,
in Endnote; duplicates will be excluded using the
Endnote function ‘remove duplicates’. The eligibility for
inclusion process will be conducted in two separate
stages:
1. Two authors will independently screen title and
abstracts of all non-duplicated papers and will
exclude those not pertinent. A ﬁnal list will be
agreed with discrepancies resolved by consensus
between the two authors. When consensus is not
reached, a third senior author will act as arbitrator. If
any doubt about inclusion exists, the article will
proceed to the next stage;
2. The full-text version of the articles passing stage 1
screening will be downloaded and assessed for eligi-
bility by two authors, independently. Discrepancies
will be resolved by consensus between the two
authors and, if needed, a third senior author will act
as arbitrator. Data from multiple reports of the same
study will be linked together. Where required, we will
contact the corresponding author to inquire on study
eligibility.
Data extraction
The following data will be collected from each included
study:
▸ Study citation, year(s) of study, year of publication,
location, setting, number of centres, design (type of
RCT), sample size, diagnostic criteria, funding/
sponsor (industry or academic);
▸ Characteristics of study participants, including:
gender distribution, mean and range of age, presence
and type of comorbid (neuro)psychiatric conditions,
mean (and SD) IQ, number randomised into each
group and number of dropouts, and whether ADHD
medications naïve at baseline or previously exposed
to other ADHD medications;
▸ Characteristics of interventions including mean and
maximum doses, formulation, add-on interventions
(if any) and whether forced dose or optimised
treatment;
▸ Time(s) of outcome measurement;
▸ Outcome measures reported including whether the
data are based on an intention-to-treat (ITT) or com-
pleters only sample. For ITT samples, methods of
imputation will be noted.
One reviewer will input outcome data into Excel. This
will be independently cross-checked by another
reviewer. Data from studies included in previous system-
atic reviews only will be extracted by one reviewer and
independently cross-checked by a second reviewer for
accuracy. Degree of agreement between the independ-
ent raters will be reported in terms of kappa coefﬁcients
and percentage agreements for main outcomes, study
and population characteristics and risk of bias items
(see below).
Risk of bias assessment
Risk of bias will be assessed for each included study
using the Cochrane Collaboration ‘risk of bias’ tool, as a
reference.50 The following ﬁve domains will be
considered:
1. Sequence generation: was the allocation sequence
adequately generated?
2. Allocation concealment: was allocation adequately
concealed?
3. Blinding of participants, personnel and outcome
assessors for each main outcome: was knowledge of
the allocated treatment adequately prevented during
the study?
4. Incomplete outcome data for the primary outcomes:
were incomplete outcome data adequately
addressed?
5. Selective outcome reporting: are reports of the study
free from suggestion of selective outcome reporting?
A description of what was reported to have happened
in each study will be provided, and a judgement on the
risk of bias will be made for each domain, based on the
following three categories: ‘high risk of bias’, ‘low risk of
bias’ and ‘unclear risk of bias’. The potential bias for
‘sponsorship bias’ will be assessed as a separate item. As
in Catala-Lopez et al,43 the overall rating of risk of bias
for each study will be the lowest rating for any of the cri-
teria (eg, if any domain is scored high risk of bias, the
study will be considered high risk of bias). Two inde-
pendent review authors will assess the risk of bias in
selected studies. Degree of agreement between the two
independent raters will be reported. Any disagreement
will be resolved through discussion and in consultation
with the principal investigators. Where necessary, the
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authors of the studies will be contacted for further
information.
Measures of treatment effect
Relative treatment effects
Continuous outcomes: where different measures are
used to assess the same outcome, data will be pooled
with standardised mean difference (SMD) Hedges’s
adjusted g.50 Dichotomous outcomes will be analysed by
calculating the OR. Results from the NMA will be pre-
sented as summary relative effect sizes (SMD or OR)
and relative 95% CIs for each possible pair of
treatments.
Relative treatment ranking
We will estimate the probability for each intervention to
be the best for each outcome, given the relative effect
sizes as estimated in NMA. Separate analyses will be con-
ducted considering lisdexamfetamine as part of amphet-
amine derivatives and as an individual drug. As
described in Salanti et al,53 we will obtain a hierarchy of
the competing interventions using the Surface Under
the Cumulative RAnking curve (SUCRA) and mean
ranks. SUCRA values will be expressed as percentage,
showing the relative probability of an intervention to be
among the best options without uncertainty.
Dealing with missing data
Missing dichotomous outcome data will be managed
according to the ITT principle, and it will be assumed
that patients in the full analysis set who dropped out
after randomisation had a negative outcome. Missing
continuous outcome data will be analysed using last
observation carried forward to the ﬁnal assessment
(LOCF) if LOCF data were reported by the trial authors;
if LOCF (or other imputation method) data are not
available, missing data will be analysed using a validated
method. We will use published SD, where available. If
SD are not available from the publication, SD will be cal-
culated from p values, t-values, CIs or SEs.54 If these
values are missing, attempts will be made to obtain SD
or p values, t-values, CIs or SEs from trial authors.
Where SDs are not available, a validated method for
imputation will be used.55 We will check that the original
SDs are normally distributed, so that the imputed SD
represents the average. Where imputation is employed,
data will be interpreted with caution, and the degree of
heterogeneity observed will need to be taken into
account when interpreting ﬁndings. A sensitivity analysis
will also be undertaken to examine the effect of imput-
ation of the ﬁndings.
Assessment of clinical and methodological heterogeneity
within treatment comparisons
The studies synthesised in each pairwise comparison
need to be similar enough in terms of patient character-
istics, setting and outcome deﬁnitions, among others, in
order to obtain interpretable and useful results.50 To
evaluate the degree of clinical and methodological het-
erogeneity, we will generate descriptive statistics for trial
and study population characteristics across all eligible
trials. We will assess the presence of clinical heterogen-
eity within each pairwise comparison by comparing
these characteristics.50
Assessment of transitivity across treatment comparisons
The assumption of transitivity underlies NMA and needs
careful evaluation. In the case that transitivity is not
plausible in a network of trials, the indirect and mixed
treatment effect estimates are not valid. To infer about
the assumption of transitivity:56
1. We will assess whether the included interventions are
similar when they are evaluated in RCTs with differ-
ent designs;
2. We will compare the distribution of the potential
effect modiﬁers across the different pairwise compari-
sons. If the distributions are balanced across compari-
sons, we will conclude against evidence of
intransitivity.57
Data analysis
Synthesis of results
First, pairwise meta-analyses will be conducted for all
outcomes and comparisons at each time point, using a
random-effects model.58 Then, an NMA will be per-
formed within a frequentist framework assuming equal
heterogeneity parameter τ across all comparisons and
accounting for correlations induced by multiarm
studies.56 59 The pairwise meta-analysis and NMA will be
performed for children/adolescents and adults, respect-
ively. The analysis will be performed using STATA V.13.
(MRC Biostatistics Unit, Cambridge, UK, http://cmimg.
cochrane.org/network-meta-analysis-toolkit); the codes
and description of the methodology can be found
in http://www.mtm.uoi.gr/index.php/stata-routines-for-
network-meta-analysis.60–62 Studies in children and ado-
lescents will be combined in the statistical analyses. For
primary outcomes, we will also assess the quality of evi-
dence using GRADE63 (GRADE Working Group
2004).63 The criteria considered are: study limitations,
indirectness, inconsistency, imprecision and reporting
bias. We will assign four levels of quality of evidence:
high, moderate, low and very low.
Assessment of statistical heterogeneity
In standard pairwise meta-analyses, we will estimate dif-
ferent heterogeneity variances for each pairwise com-
parison. In NMA, we will assume a common estimate for
the heterogeneity variance (τ2) within and across com-
parisons. The presence of statistical heterogeneity within
each pairwise comparison will be assessed by visual
inspection of the forest plots and by calculating the I2
statistic and its conﬁdence limits.64 The assessment of
statistical heterogeneity in the entire network will be
based on the magnitude of the common τ2 estimated
from the NMA models.65 For dichotomous outcomes,
8 Cortese S, et al. BMJ Open 2017;7:e013967. doi:10.1136/bmjopen-2016-013967
Open Access
the magnitude of the heterogeneity variance will be
compared with the empirical distribution as derived by
Turner et al.66
Assessment of statistical incoherence
Local and global approaches will be used to evaluate
statistical incoherence. To evaluate the presence of inco-
herence locally, we will use the loop-speciﬁc approach.67
This method evaluates the incoherence assumption by
calculating the incoherence factor as the difference
between direct and indirect estimates for a speciﬁc com-
parison in each closed loop formed by the network of
trials (using the Bucher method) and their relative 95%
CIs. The incoherence factor is the logarithm of the ratio
of two risk ratios from direct and indirect evidence in
the loop. Then we will examine whether there are any
material discrepancies; if the 95% CI does overlap with
1, the hypothesis of incoherence is not rejected, as
described in Salanti et al.68 We will assume a common
heterogeneity estimate within each loop. We will present
the results of this approach graphically in a forest plot
using the ‘ifplot’ command in STATA. To check the
assumption of consistency in the entire network, we will
use the ‘design-by-treatment’ model.69 This method
accounts for different source of inconsistency that can
occur when studies with different designs (two-arm trials
vs three-arm trials) give different results as well as dis-
agreement between direct and indirect evidence. Using
this approach, we will infer the presence of inconsistency
from any source in the entire network based on a χ2
test. The design-by-treatment model will be performed
in STATA using the ‘mvmeta’ command. Inconsistency
and heterogeneity are interweaved; to distinguish
between these two sources of variability, we will employ
the I2 for inconsistency that measures the percentage of
variability that cannot be attributed to random error or
heterogeneity (within comparison variability).65
Investigation of heterogeneity and inconsistency
In the case of important clinical or statistical inconsist-
ency, the feasibility of multiple-treatments meta-
regression or subgroup analysis will be considered to
investigate the possible sources of heterogeneity and
incoherence by using the following effect modiﬁers (for
primary outcomes only):
1. studies sponsored versus those not sponsored by
pharmaceutical companies;
2. males versus females;
3. children versus adolescents, since some medications
(eg, SSRIs) have been reported to have different efﬁ-
cacy in children versus adolescents;70 (if study data
are not available for children (aged ≤12 years) and
adolescents (aged >12) separately, they will only be
included in the main analysis (ie, combining children
and adolescents together—see the Synthesis of
results section)).
Sensitivity analyses
We will explore the feasibility of conducting the follow-
ing sensitivity analyses by excluding:
1. studies where all participants have IQ< 70;
2. studies where all participants have psychiatric/neuro-
logical comorbidities;
3. studies lasting <2 weeks;
4. studies for which imputation of missing data was
required;
5. studies with overall high or unclear risk of bias;
6. crossover trials;
7. studies including patients resistant to ADHD
medication;
8. studies recruiting only non-treatment-naïve patients;
A ﬁnal sensitivity analysis will address whether unba-
lanced doses affected the results. To exclude trials with
non-equivalent comparisons, we will apply a previously
validated approach used for antidepressant trials.71 For
this, we put together a roster (see tables 2 and 3) in
which low and high doses of the drugs included in the
present NMA are described. Tables 2 and 3 are based
on FDA indications. This roster will be employed to
detect inequalities in dosing that could affect compara-
tive efﬁcacy by excluding trials with low doses of one
drug and high doses of the other (or vice-versa). We will
not consider starting doses if these were supposed to be
increased during the trial.
DISSEMINATION
The results of this study will be published in a peer-
reviewed journal and will be also possibly presented at
national and international meetings of (child) psych-
iatry, psychology and paediatrics.
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